The goal is never filling your stomach more than halfway
In the phase 1b/2a clinical trial with amycretin, an unimolecular GLP-1, and amylin RA intended for OW SC use, the 125 individuals with overweight or obesity included in the study achieved an estimated body weight loss of 9.7% on 1.25 mg (20 weeks), 16.2% on 5 mg (28 weeks) and 22.0% on 20 mg following 36 weeks of treatment [127]
These conditions include metabolic syndrome [11, 12], diabetes [4], high blood pressure, atherosclerosis [13], ischemia-reperfusion injury [13], cancer [14, 15], and various neurodegenerative disorders [16]
& Milstein, C
Below are some of the most promising peptides for arthritis and chronic joint pain being explored worldwide